

Progenitor cells from gene-engineered human induced pluripotent stem cells as synthetic cancer alternatives

Background:

Recent studies revealed limitations in genetic stability and recapitulating accurate pathophysiological properties of patient-derived (PD) cancer models opposing challenges for reproducible and translational research. In an attempt to develop functional cancer test systems in alternative to PD models, we have genetically engineered a portfolio of isogenic human induced pluripotent stem cells with different pan-cancer relevant onco-protein signatures.

Results:






Fig2: Protein-level validation of stable oncogene activation in human induced pluripotent stem cells (hiPSC, commercial cell lines)





Fig3: Differentiation in tissue-specific progenitors (in this case neural differentiation) meanwhile maintaining stable oncogene expression




Fig 6: Introduction of point mutations via base-editing, adjusted after Komor et al., 2016

References:
[1] Uhlmann et al., 2022;
[2] Kahn et al., 2021;